Charcot-Marie-Tooth (CMT) disease is the most common hereditary neuromuscular disorder. This study involves the entire known CMT patient registry in Gran Canaria, represented by 256 patients belonging to 79 unrelated families, who were clinically and genetically characterized, along with physical and neurophysiological evaluation on 181 and 165 patients, respectively.
The two most common clinical forms are CMT1, a demyelinating neuropathy and CMT2, representing axonal neuropathy are inherited as autosomal dominant, recessive, or X-linked traits, respectively. 2 The most common demyelinating phenotype, CMT1A, is mostly associated with a duplication of the 17p11.2 locus, encompassing the PMP22 gene. [4] [5] [6] Hereditary neuropathy with liability to pressure palsies (HNPP) is another dominant trait caused by deletion of the 17p11.2 region, but also by point mutations of the PMP22 gene.
5
CMT2 is mainly associated with mutations in the MFN2, MPZ, and GDAP1 genes, 7 while mutations in the GJB1 gene are associated with X-linked CTMX, with both demyelinating and axonal features. 8 Despite a great number of studies on this common neuropathy, the lack of genetic testing in some cases has defied the definition of specific phenotypes in sufficiently large genetically homogeneous cohorts. Herein, we describe the characteristics of a large cohort of genetically homogeneous patients with CMT disease carrying the PMP22 gene duplication. These patients belong to families from the island of Gran Canaria, a population that may be considered a genetic isolate. 9 2 | MATERIALS AND METHODS 
| Study design and patient population

| Demographic and clinical data
All neurological examinations were performed by the same neurologist (ML). Any postural hand tremor was identified by direct observa- 
| Genetics and epidemiology
We identified 256 subjects with CMT disease in Gran Canaria, the vast majority born in the island (>97%), who were subjected to genetic analysis. Abbreviations: HNPP, hereditary neuropathy with liability to pressure palsies; NCV, nerve conduction velocity. Data shown are medians (IQR) and frequencies/total (%); ages are expressed in years. a Diagnosis based on nerve conduction velocity, compound muscle action potential, and sensory nerve action potential.
| Clinical study
All CMT patients willing to participate were included in this initial study. Initially, 256 patients with CMT were finally evaluated (51.2% males and 48.8% females) from 79 families, and defined demographic characteristics, age at exploration and symptoms of the study cohort according to the type of genetic mutation ( Table 2 ). As seen, the mean age at examination was 30 years (range: 14;48), although the onset of the disease in patients with CMT1A was as early as 3 years of age, accompanied by walking difficulties in 115 of a total of 201 patients (Table 2) . Feet cramps, the second most common manifestation, present in 40.08% of all patients examined, also appeared early in this group, at the mean age of 20 (range: 11;40) vs 38 years (25;50) of age in the group of patients with a deletion of this locus ( Table 2) .
Out of the group of 256 patients, a thorough neurological examination was carried out only in 181 patients who accepted for participating (137 with CMT1A, 34 with HNPP and 10 with axonal CMT).
Features strongly associated with the CMT1A phenotype were pes cavus, either alone or in combination with hammer toes, hammer toes only, kyphosis, and postural tremor in arms (Table 3 ). All these neurological observations were related to severe anatomical lesions that were predominant in the CMT1A group, such as atrophy of tibialis anterior, gastrocnemius, and hands. Muscular atrophy was accompanied by severe and moderate paresis, only evident for these muscles in the CMT1A group as compared with the group with HNPP. By contrast, psoas, cuadriceps, and crural triceps were unaffected in all groups. Bilateral tongue atrophy was observed in a similar proportion in both CMT1A and HNPP groups (5.8 vs 5.9) (Figure 1 ).
Areflexia was another characteristic defining these patients. Both upper and lower limbs reflexes, evaluated at the triceps, brachioradialis, and patellar levels, showed a much greater impairment in CMT1A
in comparison with HNPP patients.
Sensory perception evaluation showed a remarkable, mostly distal, hypoesthesia to touch, puncture and vibration in the CMT1A group (Table 3) .
From the group of 181, 165 patients (123 with CMT1A, 32 with HNPP and 10 with axonal CMT) had, at least, one electrophysiological evaluation. As shown, characteristic electrophysiological were observed for each phenotypic group (Table 3) . 
| DISCUSSION
We describe, to the best of our knowledge, the largest group of CMT1A patients with a duplication of the locus at 17p11.2 reported to date. Being the most abundant genetic variation leading to CMT disease, the 17p11.2 duplication been studied in depth. 4, 6 Nonetheless, our study provides a unique opportunity to describe its phenotype in a homogeneous ethnic group where over 97% are native to the island of Gran Canaria. We also find one of the highest prevalences reported to date, only behind the eastern Akershus County in Norway 20 and similar to what has been found in Northen Ostrobothnia (Finland) 21 and in another spanish study centered on the Cantabria region. 22 However, the Norway study only provides 28.6% of patients with a molecular diagnosis, the finnish study up to 55%, while the Cantabria study shows no molecular testing at all. Molecular testing not only allows an accurate diagnosis, but also provides information about the precise etiology of the disease. A higher number of patients have been molecular diagnosed in another Spanish study in Valencia (365 out of 438), but the overall prevalence of CMT in the region was not estimated. 23 Therefore, we believe that these studies are not comparable to ours, and that the prevalence numbers that we provide are more precise from a genetic standpoint. However, one limitation of our study is that we only report those cases who wished to participate and where the clinical diagnosis had been ascertained with genetical analysis and, therefore, we feel that we are underestimating the real prevalence of the disease in Gran Canaria. Table 4 summarizes our findings in comparison with other studies. phenotype, most of them with duplication of the genomic locus containing the PMP22 gene. This is probably due to the characteristics of the population in Gran Canaria, which may be considered as a genetic isolate, based on a higher-than-expected prevalence observed for Mendelian disorders associated with founder mutations. 9, 41 This high proportion of patients presenting with CMT1A parallels those obtained in another genetic isolate, such as Iceland (84%) 42 and in the northeastern region of Italy (82.4%). 39 An advantage of having a large cohort with such a genetic homogeneity, besides the simplification of a molecular testing approach, is that it allows to define precisely the clinical phenotype within the group. The mean age of onset was much earlier in CMT1A patients (5 years) than those with HNPP (20 years) (Figure 2 ). This earlier onset usually debut with walking difficulties in a large fraction of the patients presenting with the duplication (57%) vs the deletion (11%), and was earlier than those reported in other studies, ranging from 11.6 43 to 19.4 years old. 4 Postural tremor in hands was detected in 43% of patients in the CMT1A group, a larger proportion than those observed in other studies, where this characteristic was observed only in 5% 4 or 8.5% of the patients. 43 Bilateral tongue atrophy was an additional phenotype that we observed in a similar proportion in both CMT1A and HNPP groups 44 None underwent orthopedic surgery to correct severe skeletal deformities. 45 
| CONCLUSIONS
In summary, our study showed a classical CMT1A phenotype, in agreement with others, 4, 6, 43 being the most remarkable differences the age of onset, much earlier in our CMT1A cohort, and the frequency of appearance of postural hand tremor. As a preventive measure, genetic counseling, either as prenatal testing and/or preimplantation genetic diagnosis, is not always considered. 46 However, given the importance of mutation detection not only in the diagnosis, but also in the clinical course of the disease, we would like to emphasize this approach, especially in populations, such as ours, where the presence of founder mutations, affecting most of the patients, largely simplifies genetic screening. 
